Full Press Release Details
Supernus Pharmaceuticals Targeted in Ransomware
The attack had no significant impact on the
business and did not cause any significant disruption to Company's operations
No ransom payments have been made by the
Md., Nov. 24, 2021 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced
that it was the recent target of a ransomware attack. The attack had no significant impact on the business and did not cause any serious
disruption to the Company's operations. The Company continues to operate without interruption and does not currently anticipate
paying any ransom amounts to any criminal ransomware group.
The Company currently believes the incident began around mid-November,
2021. Based on the preliminary results of the ongoing investigation, the Company believes the criminal ransomware group encrypted certain
files on the Company's systems, deployed malware to impede access to the Company's systems, and thereafter threatened to publish
certain data copied from the Company's systems. Upon detection of the ransomware, the Company notified government authorities, engaged
cybersecurity experts and its outside law firm, and commenced its recovery process. The Company successfully recovered the impacted files
and has taken additional steps designed to further protect its networks and files.
To date, the Company has not paid any ransom and has been able to restore
all of the information encrypted by the criminal ransomware group.
Although to date the Company's business and operations have not
been significantly impacted by the incident, there is no assurance that further attacks may not significantly impact the Company's
business or operations and that information improperly obtained by the criminal ransomware group may not be exploited by the criminal
ransomware group or other third parties. The Company will take appropriate action to protect any stolen confidential information and will
continue to investigate the incident and monitor the situation going forward.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on
developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for
epilepsy, migraine, ADHD, hypomobility in Parkinson's disease, cervical dystonia and chronic sialorrhea. We are developing a broad
range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson's disease, epilepsy, depression
and rare CNS disorders.
more information, please visit www.supernus.com.
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com